Targeting the retinoic acid signaling pathway for mitigating visual impairmen in retinal degenerative disorders
靶向视黄酸信号通路以减轻视网膜退行性疾病中的视力障碍
基本信息
- 批准号:10684166
- 负责人:
- 金额:$ 48.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAcuteAge related macular degenerationAlcoholismAmacrine CellsAnimal ModelBehaviorBehavioralBlindnessBrainCellsChemicalsClinical ResearchConsciousContrast SensitivityDarknessDegenerative DisorderDeteriorationDiseaseDissociationDisulfiramDominant-Negative MutationElectrophysiology (science)Enzyme InhibitionEnzymesFDA approvedFrequenciesFunctional disorderGene ExpressionGenerationsGenesGenetic TranscriptionGoalsHistologicHumanHyperactivityImpairmentIndividualInterneuronsLightLight CellMeasuresMorphologyMusNeuronsPharmaceutical PreparationsPharmacotherapyPhenotypePhotophobiaPhotoreceptorsProcessProductionProteinsReporterReportingRetinaRetinal ConeRetinal DegenerationRetinal DiseasesRetinal Ganglion CellsRetinitis PigmentosaRetinoic Acid ReceptorSignal PathwaySignal TransductionSynapsesSynaptic TransmissionTestingTetracyclinesTherapeuticTimeToxic effectTrainingTransgenic MiceTretinoinVertebrate PhotoreceptorsViralVisionVisualVisual impairmentavoidance behaviorbehavior testcellular targetingdrug repurposingexperimental studygene therapyimprovedin vivoinhibitormouse modelmulti-electrode arraysoptogeneticspatch clampphotoreceptor degenerationpresynaptic neuronsresponseretinal neuronsafety assessmentsafety testingsmall moleculespatial visiontranslation to humanstransmission processvisual informationvisual learning
项目摘要
ABSTRACT
Light responses are initiated in rod and cone photoreceptors, processed by retinal interneurons, and synaptically
transmitted to retinal ganglion cells (RGCs), which send information, in the form of spike trains, to the brain. In
degenerative retinal disorders, including Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa
(RP), the photoreceptors gradually die off, depriving downstream neurons of light-sensitive input. However,
recent evidence suggests that losing photoreceptors is only part of the problem in these disorders. Downstream
retinal neurons become hyperactive, with retinal ganglion cells (RGCs) firing spontaneously in darkness at up to
10 times faster than in healthy retina, corrupting the proper encoding of visual information. We recently reported
that retinoic acid (RA), a small molecule that activates gene transcription, is the signal that triggers RGC
hyperactivity. Blocking the receptor for RA in vivo can reverse hyperactivity, unmasking light responses that
would otherwise be obscured by spontaneous RGC firing. Blocking RA receptors in the retina also augments
the contrast-sensitivity of learned visual behaviors in a mouse model of RP. Our goal in this project is to assess
whether drugs or gene therapies that inhibit RA signaling can improve vision in mouse models of RP, with the
hope of extending useful vision for years in humans with degenerative retinal disorders. First, we will ask whether
inhibiting RA signaling not only improves light-sensitivity, but actually improves conscious visual function in
vision-impaired mice, assessed with behavioral tests of contrast sensitivity and spatial frequency threshold. We
will determine how when during the degeneration process RA inhibitors are most effective, revealing the optimal
time for beginning treatment. Second, we will investigate retinal neurons that lie upstream of RGCs, namely
bipolar cells and amacrine cells. We will ask whether pathophysiological changes in these presynaptic neurons
are also induced by elevated RA signaling and whether inhibiting RAR can reverse these changes, providing
critical information for effective cellular targeting of gene therapy. Third, we will test whether vision can be
improved by inhibiting the enzyme that synthesizes RA, with a re-purposed drug that is already FDA-approved
for other indications, paving the way for human clinical studies. Taken together, this project will establish the
proof-of-principle behind a new treatment paradigm for augmenting vision in retinal degenerative disorders.
摘要
光反应起始于视杆和视锥感光细胞,由视网膜中间神经元处理,并通过突触进行。
传输到视网膜神经节细胞(RGC),后者以棘波序列的形式将信息发送到大脑。在……里面
退行性视网膜疾病,包括老年性黄斑变性(AMD)和视网膜色素变性
(RP),光感受器逐渐死亡,剥夺了下游神经元的光敏输入。然而,
最近的证据表明,光感受器的丧失只是这些疾病问题的一部分。下游
视网膜神经元变得过度活跃,视网膜神经节细胞(RGC)在黑暗中自发放电,最高可达
比健康的视网膜快10倍,破坏了视觉信息的正确编码。我们最近报道了
维甲酸(RA),一种激活基因转录的小分子,是触发RGC的信号
多动症。阻断体内RA受体可以逆转过度活动,揭开光反应的面纱
否则会被自发的RGC发射所遮挡。阻断视网膜中的RA受体也会增加
在RP小鼠模型中学习的视觉行为的对比敏感性。我们在这个项目中的目标是评估
无论是抑制RA信号的药物还是基因疗法都可以改善RP小鼠模型的视力,
希望在患有退行性视网膜疾病的人类中延长有用的视力数年。首先,我们将询问是否
抑制RA信号不仅提高了对光的敏感度,而且实际上还改善了有意识的视觉功能
视力受损的小鼠,用对比敏感度和空间频率阈值的行为测试进行评估。我们
将确定在退变过程中何时RA抑制剂最有效,揭示最佳
开始治疗的时间到了。其次,我们将研究位于视网膜节细胞上游的视网膜神经元,即
双极细胞和无长突细胞。我们将询问这些突触前神经元的病理生理变化
也是由RA信号升高诱导的,以及抑制RAR是否可以逆转这些变化,提供
有效的细胞靶向基因治疗的关键信息。第三,我们将测试视觉是否可以
通过抑制合成RA的酶来改进,使用一种已经得到FDA批准的重新用途的药物
用于其他适应症,为人类临床研究铺平道路。综上所述,该项目将建立
视网膜退行性疾病增加视力的新治疗范例背后的原则证明。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD H KRAMER其他文献
RICHARD H KRAMER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD H KRAMER', 18)}}的其他基金
An electro-mechanical mechanism of spike propagation in myelinated axons
有髓轴突中尖峰传播的机电机制
- 批准号:
10194107 - 财政年份:2021
- 资助金额:
$ 48.48万 - 项目类别:
Probing GABAa receptor function and plasticity with light
用光探测 GABAa 受体功能和可塑性
- 批准号:
9286699 - 财政年份:2017
- 资助金额:
$ 48.48万 - 项目类别:
Targeting the retinoic acid signaling pathway for mitigating visual impairmen in retinal degenerative disorders
靶向视黄酸信号通路以减轻视网膜退行性疾病中的视力障碍
- 批准号:
10298375 - 财政年份:2015
- 资助金额:
$ 48.48万 - 项目类别:
Targeting the retinoic acid signaling pathway for mitigating visual impairmen in retinal degenerative disorders
靶向视黄酸信号通路以减轻视网膜退行性疾病中的视力障碍
- 批准号:
10475753 - 财政年份:2015
- 资助金额:
$ 48.48万 - 项目类别:
Targeting the retinoic acid signaling pathway for mitigating visual impairmen in retinal degenerative disorders
靶向视黄酸信号通路以减轻视网膜退行性疾病中的视力障碍
- 批准号:
10844853 - 财政年份:2015
- 资助金额:
$ 48.48万 - 项目类别:
Understanding How Photoswitches Restore Visual Function in Blind Mice
了解光电开关如何恢复失明小鼠的视觉功能
- 批准号:
9330653 - 财政年份:2015
- 资助金额:
$ 48.48万 - 项目类别:
Understanding how photoswitches restore visual function in blindness
了解光电开关如何恢复失明者的视觉功能
- 批准号:
10212754 - 财政年份:2015
- 资助金额:
$ 48.48万 - 项目类别:
A universal photoswitch system for optical control of neuronal receptors
用于神经元受体光学控制的通用光电开关系统
- 批准号:
7726422 - 财政年份:2009
- 资助金额:
$ 48.48万 - 项目类别:
A universal photoswitch system for optical control of neuronal receptors
用于神经元受体光学控制的通用光电开关系统
- 批准号:
8255457 - 财政年份:2009
- 资助金额:
$ 48.48万 - 项目类别:
A universal photoswitch system for optical control of neuronal receptors
用于神经元受体光学控制的通用光电开关系统
- 批准号:
7898562 - 财政年份:2009
- 资助金额:
$ 48.48万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 48.48万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 48.48万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 48.48万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 48.48万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 48.48万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 48.48万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 48.48万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 48.48万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 48.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 48.48万 - 项目类别:
Standard Grant